Publicaciones en colaboración con investigadores/as de Universidade de São Paulo (11)

2023

  1. Evolving Management Paradigm for Stable Ischemic Heart Disease Patients: JACC Review Topic of the Week

    Journal of the American College of Cardiology, Vol. 81, Núm. 5, pp. 505-514

2022

  1. Sustained Safety and Performance of a Second-Generation Sirolimus-Eluting Absorbable Metal Scaffold: Long-Term Data of the BIOSOLVE-II First-in-Man Trial at 5 Years

    Cardiovascular Revascularization Medicine, Vol. 38, pp. 106-110

  2. Transcatheter versus surgical aortic valve replacement in patients with morbid obesity: a multicentre propensity score-matched analysis

    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, Vol. 18, Núm. 5, pp. e417-e427

2021

  1. Impact of Endothelial Shear Stress on Absorption Process of Resorbable Magnesium Scaffold: A BIOSOLVE-II Substudy

    Cardiovascular Revascularization Medicine, Vol. 29, pp. 9-15

2019

  1. First Report of Edge Vascular Response at 12 Months of Magmaris, A Second-Generation Drug-Eluting Resorbable Magnesium Scaffold, Assessed by Grayscale Intravascular Ultrasound, Virtual Histology, and Optical Coherence Tomography. A Biosolve-II Trial Sub-Study

    Cardiovascular Revascularization Medicine, Vol. 20, Núm. 5, pp. 392-398

  2. Impact of procedural characteristics on coronary vessel wall healing following implantation of second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary artery lesions: An optical coherence tomography analysis

    European Heart Journal Cardiovascular Imaging, Vol. 20, Núm. 8, pp. 916-924

  3. Serial 3-Dimensional Optical Coherence Tomography Assessment of Jailed Side-Branch by Second-Generation Drug-Eluting Absorbable Metal Scaffold (from the BIOSOLVE-II Trial)

    American Journal of Cardiology, Vol. 123, Núm. 7, pp. 1044-1051

2018

  1. In vivo serial invasive imaging of the second-generation drug-eluting absorbable metal scaffold (Magmaris — DREAMS 2G) in de novo coronary lesions: Insights from the BIOSOLVE-II First-In-Man Trial

    International Journal of Cardiology, Vol. 255, pp. 22-28

2016

  1. Rationale and design of the SYNTAX II trial evaluating the short to long-term outcomes of state-of-the-art percutaneous coronary revascularisation in patients with de novo threevessel disease

    EuroIntervention, Vol. 12, Núm. 2, pp. e224-e234

  2. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial

    The Lancet, Vol. 387, Núm. 10013, pp. 31-39

  3. Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial

    European Heart Journal, Vol. 37, Núm. 35, pp. 2701-2709